Argent BioPharma Clears Secondary Trading for New Share Issue

Argent Biopharma ( (AU:RGT) ) just unveiled an announcement.

Argent BioPharma has notified investors of the issue of 1,250,000 fully paid ordinary shares, confirming that the securities were issued without a disclosure document under Australian law but qualify for on-sale under the relevant exemption. The company stated it remains compliant with its financial reporting and continuous disclosure obligations and affirmed there is no undisclosed information material to assessing its financial position or the rights attaching to the new shares, aiming to provide regulatory clarity and reassurance to shareholders.

This share issuance notice formalizes secondary trading eligibility for the new Argent BioPharma shares on the Australian market, reducing legal uncertainty for investors who may wish to trade them. By emphasizing its ongoing compliance and the absence of withheld market-sensitive information, the company underlines its governance standards and seeks to maintain confidence as it advances its neuro-immune focused drug pipeline.

The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent BioPharma Ltd. is a clinical-stage biopharmaceutical company developing nano‑engineered medicines aimed at restoring balance between the nervous and immune systems. Its lead candidates, CannEpil and CimetrA, target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, supported by proprietary delivery platforms that enhance blood–brain and alveolar–capillary barrier penetration.

Average Trading Volume: 192,762

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$3.96M

See more insights into RGT stock on TipRanks’ Stock Analysis page.